From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Women's Health>
  4. Summary and Comment

Novel Influenza A (H1N1) Infections Reported in Pregnant Women

The CDC recommends that pregnant women with confirmed, probable, or suspected novel influenza A (H1N1) infection receive antiviral therapy with oseltamivir (Tamiflu).

Pregnancy raises risk for complications related to seasonal as well as pandemic influenza infections such as those caused by the novel influenza A (H1N1) virus. The CDC has recently summarized information about novel H1N1 infection during pregnancy and has issued preliminary treatment recommendations.

Twenty cases of novel H1N1 (15 confirmed and 5 probable) in pregnant women have been reported in the U.S. as of May 10, 2009. Three women were hospitalized, and one of them died. Based on available data, the CDC recommends that pregnant women with confirmed, probable, or suspected novel H1N1 infection receive antiviral therapy with oseltamivir (Tamiflu; preferred for its systemic absorption) for 5 days. Therapy should be initiated as soon as possible, even if >48 hours have elapsed since symptom onset. Acetaminophen should also be administered, as fevers are associated with adverse maternal and fetal outcomes. Pregnant women who have had close contact with someone who has confirmed, probable, or suspected novel H1N1 infection should receive prophylaxis with either oseltamivir or zanamivir (Relenza) for 10 days.

Comment: Both the Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend annual influenza vaccination for all pregnant women. However, because the 2008–2009 seasonal vaccine does not protect against novel H1N1, even vaccinated pregnant women with flu-like symptoms should be evaluated and treated. Although the safety and efficacy of oseltamivir during pregnancy have not been firmly established, the benefits of this antiviral drug are likely to outweigh the risks. Novel H1N1 seems to be resistant to amantadine and rimantadine, so these drugs should not be used in people with suspected novel H1N1 infection.

Anna Wald, MD, MPH

Published in Journal Watch Women's Health May 18, 2009

Citation(s):

Centers for Disease Control and Prevention (CDC). Novel influenza A (H1N1) virus infections in three pregnant women — United States, April–May 2009. MMWR Morb Mortal Wkly Rep 2009 May 15; 58:497.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2009. Massachusetts Medical Society. All rights reserved.